Zobrazeno 1 - 10 of 5 553 pro vyhledávání: '"Endoxifen"'
1
Akademický článek
Auraptene Boosts the Efficacy of the Tamoxifen Metabolites Endoxifen and 4-OH-Tamoxifen in a Chemoresistant ER+ Breast Cancer Model.
Autor: Pulido-Capiz, Angel1,2 (AUTHOR) pulido.angel@uabc.edu.mx, Chimal-Vega, Brenda1,2 (AUTHOR) brenda.chimal@uabc.edu.mx, Avila-Barrientos, Luis Pablo3 (AUTHOR) luispablo.barrientos@mpimp-golm.mpg.de, Campos-Valenzuela, Alondra1,2 (AUTHOR) campos.alondra85@uabc.edu.mx, Díaz-Molina, Raúl1,2 (AUTHOR) rauldiaz@uabc.edu.mx, Muñiz-Salazar, Raquel4 (AUTHOR) ramusal@uabc.edu.mx, Galindo-Hernández, Octavio1,2 (AUTHOR) octavio.galindo@uabc.edu.mx, García-González, Victor1,2 (AUTHOR) vgarcia62@uabc.edu.mx
Publikováno v: Pharmaceutics. Sep2024, Vol. 16 Issue 9, p1179. 20p.
Zobrazit plný text záznamu
2
Akademický článek
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort.
Autor: Mc Laughlin AM; Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany.; PharMetrX Graduate Research Training Program, Berlin/Potsdam, Germany., Helland T; Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.; Hormone Laboratory, Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway., Klima F; Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany.; PharMetrX Graduate Research Training Program, Berlin/Potsdam, Germany., Koolen SLW; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands., van Schaik RHN; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands., Neven P; Department of Gynecological Oncology and Multidisciplinary Breast Center, University Hospitals Leuven, Leuven, Belgium., Swen JJ; Department Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, the Netherlands., Guchelaar HJ; Department Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, the Netherlands., Dalenc F; Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France.; Cancer Research Center of Toulouse (CRCT), Inserm U1037, Université Paul Sabatier, Toulouse, France., White-Koning M; Cancer Research Center of Toulouse (CRCT), Inserm U1037, Université Paul Sabatier, Toulouse, France., Michelet R; Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany., Mikus G; Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany.; Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany., Schroth W; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.; University Tübingen, Tübingen, Germany., Mürdter T; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.; University Tübingen, Tübingen, Germany., Brauch H; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.; University Tübingen, Tübingen, Germany.; iFIT Cluster of Excellence, University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany., Schwab M; University Tübingen, Tübingen, Germany.; iFIT Cluster of Excellence, University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany.; Departments of Clinical Pharmacology, and of Biochemistry and Pharmacy, University of Tübingen, Tübingen, Germany., Søiland H; Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Research, Stavanger University Hospital, Stavanger, Norway., Mellgren G; Hormone Laboratory, Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway., Thomas F; Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France.; Cancer Research Center of Toulouse (CRCT), Inserm U1037, Université Paul Sabatier, Toulouse, France., Kloft C; Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany., Hertz DL; Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.
Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2024 Sep; Vol. 116 (3), pp. 690-702. Date of Electronic Publication: 2024 Mar 18.
Zobrazit plný text záznamu
3
Akademický článek
Endoxifen in Treatment of Individuals with Borderline Personality Disorder with Predominant Impulsivity: A Case Series
Autor: Debanjan Banerjee, Rajashree Ray
Publikováno v: Consortium Psychiatricum, Vol 4, Iss 4, Pp 66-73 (2023)
Endoxifen, a protein kinase C inhibitor, has been approved for use in manic episodes in India. One of the symptom traits that it predominantly targets is impulsivity. Impulsivity can also be a symptom dimension of other mental health conditions, one
Externí odkaz: https://doaj.org/article/10d12dc157a44f5cafa65d397a0e9f8a
Zobrazit plný text záznamu
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
Akademický článek
Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder.
Autor: Ahmad, Ateeq1 (AUTHOR), Sheikh, Saifuddin1 (AUTHOR), Khan, Mujtaba Ali2 (AUTHOR), Chaturvedi, Alok2 (AUTHOR), Patel, Piyush2 (AUTHOR), Patel, Ronak3 (AUTHOR), Buch, Bakul Chandrakant4 (AUTHOR), Anand, Rajendra Someshwar5 (AUTHOR), Shah, Timirkumar Chandrakant6 (AUTHOR), Vora, Vaishal Nareshchandra7 (AUTHOR), Ramasubramanian, Vikhram8 (AUTHOR), Rao, Satyanarayana9 (AUTHOR), Kumar, Narendra10 (AUTHOR), Prasad, B. S. V.11 (AUTHOR), Sathianathan, Ramanathan12 (AUTHOR), Verma, Kamal Kumar13 (AUTHOR), Jhanwar, Venu Gopal14 (AUTHOR), Kumar, Nand15 (AUTHOR), Shah, Sandip16 (AUTHOR), Dalal, Pronob Kumar17 (AUTHOR)
Publikováno v: Bipolar Disorders. Sep2021, Vol. 23 Issue 6, p595-603. 9p. 5 Charts, 2 Graphs.
Zobrazit plný text záznamu
8
Akademický článek
The Antimanic Effect of Endoxifen in Patients with Bipolar Disorder with Renal Comorbidities: Case Series.
Autor: Kuraria, Astut1 (AUTHOR), Vishwanath, Rashmi1 (AUTHOR), Nagaraj, Anil Kumar M.1 (AUTHOR), Soman, Savitha1 (AUTHOR), Kamath, Avinash1 (AUTHOR)
Publikováno v: Indian Journal of Psychological Medicine. Sep2024, p1.
Zobrazit plný text záznamu
9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
10
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje